- Parnell acquired U.S.-based manufacturer Noble Pharma LLC
- Deal adds FDA- and DEA-accredited facility in Wisconsin to Parnell’s operations
- Acquisition enhances manufacturing capacity and supply chain reliability
- Supports expansion of Parnell’s product portfolio across companion and production animals
- Positions company for continued growth and innovation in the U.S. market
Parnell has announced the acquisition of Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, in a move aimed at expanding its manufacturing capabilities and strengthening its presence in the United States.
Expanding U.S. manufacturing capabilities
The acquisition brings an FDA- and DEA-accredited production facility in Menomonie, Wisconsin into Parnell’s operational network. Noble Pharma’s capabilities include manufacturing a wide range of dosage forms, such as suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments.
By integrating these capabilities, Parnell aims to improve supply continuity and support the growing demand across its expanding portfolio of animal health products.
Supporting growth and supply reliability
Company leadership described the acquisition as a strategic milestone in advancing long-term operational goals. The addition of a U.S.-based manufacturing footprint is expected to enhance product availability, streamline distribution, and strengthen partnerships with customers and distributors.
The move also positions Parnell to scale production and accelerate innovation as it continues to expand in the U.S. animal health market.
Strategic outlook
With operations spanning multiple countries, Parnell focuses on developing and commercializing veterinary pharmaceuticals for both companion and production animals. The acquisition of Noble Pharma aligns with the company’s broader strategy to invest in infrastructure that supports quality, consistency, and growth.
Financial terms of the transaction were not disclosed.
Information sourced from the company’s press release.
